论文部分内容阅读
背景在同种干细胞移植时,体外增殖和扩增白血病反应性T细胞可改善针对血液恶性肿瘤细胞免疫疗法的疗效和特异性。由于次要组织相容性抗原HA-1H的表达限于造血细胞,在体外增殖HA-1H特异CD8+细胞毒性T淋巴细胞(CTLs)能用于免疫治疗。研究设计与方法很多研究已证实早期CTL的诱导需要专门的抗原递呈细胞。当CD4+T细胞在最初的
Background The proliferation and expansion of leukemia-reactive T cells in vitro at the same type of stem cell transplantation can improve the efficacy and specificity of immunotherapy against hematological malignancies. Since the expression of the secondary histocompatibility antigen HA-1H is restricted to hematopoietic cells, proliferation of HA-1H-specific CD8 + cytotoxic T lymphocytes (CTLs) in vitro can be used for immunotherapy. Research Design and Methods Many studies have demonstrated that induction of early CTL requires specialized antigen-presenting cells. When CD4 + T cells are initially